- Email: [email protected]
169 Tissue plasminogen activator and plasminogen activator inhibitor in aqueos humor of the human eye
POSTER PRESENTATIONS P-VII Fibrinolysis in Non-Vascular Diseases
169
170
TISSUE PLASMINOGEN ACTIVAIOR AND PLASMINOGEN ACTIVATOR INHIBITOR IN AQUEOS HUMOR OF THE HUMAN EYE
t-PA, u-PA AND SOME OTHER FIBRINOLYTIC PARAMETERS IN N O D ~ PARENCHYMATOUS GOITRE AND GRAVES DISEASE 'Zastawna E., 2Drewniak W., 'Ro~ D., 'Zekanowska E ,
~Giedroj6 J,
1Bielawiec Stankiewicz A
M,
iDepartment of Hematology, University Medical School,
2Walkowiak
M,
iGalar
M,
20epartment of Ophthalmology Bialystok, Poland.
In the anterior segment of the eye, fibrin clots must be rapidly resorbed to prevent fibrosis. Tissue-type plasminogen activator (t-PA), a serine protease that catalyzes the conversion from plasminogen to plasmin plays an important role in the fibrinolytic system and has also in recent years attracted attention in the field of ophthalmology. ~he aqueous humor of patients undergoing cataract surgery was analyzed for the presence of components of the fibrinolytic cascade. The quantities of t-PA and plasminogen-activator inhibitor (PAl) were determined by using enzyme-linked immunosorbent assays. We determined t-PA and PAI in the aqueous humor of 64 patients between 59 and 82 years age. The t-PA levels ranged from 0.65 to 1.75 ng/ml and PAl activity from 3.24 to 5.1 AU/ml. Association between t-PA levels and PAI activity and acompanying diseases or metabolic disorders was noted. The highest concentration of t RA and the lowest activity of PAI in aqueous humor of patients with senile cataract has been observed. The knowledge about the presence of t-PA in aqueous humor is a equisite for the recognition of pathological events following intraocular fibrin formation and may be important basis for therapeutic use of t-PA.
'Gbralczyk B., 'Michalski A., 'Kotschy M.
Departments of'Pathophysiolo~, 2Endocrinolo~ and Diabetolosy, University School of Medical Sciences, Bydgo~zcz, Poland The aim of study was to compare the fibrinolytic potential in patients suffering fi'om nodular pafenchymatons goilre (rip.g) and Graves disease (G.d.),The study was performed in the blood plasma of 19 patients aged 19-53 (mean 34) with np.g. and in 8 patients aged 22-45 (mean 37) with G.d..Control group consisted of 22 healthy persons aged 24-50 (mean 36) .The following determinations were performed : t-PA and u-PA antigen and activity, PAI-1 activity, PAL2 antigen and PAP complexes.
Results: Parameters [twits]
Controls
rtp.g
G.d
n=14 n=19 n--8 9,10 ± 4,17 * 4,36 ±2,25 t-PA antigen [ng/ml] 5,62 + 3,72 0,81 + 0,46 t-PA activity [IU/mi] 0,52 + 0,21 0,56 + 0,33 0,53 ± 0,10 u-PA antigen [ng/ml] 0,59 ± 0,19 0,49 + 0,22 0,35 ± 0,08 0,37 + 0,13 u-PA activity [ng/ml] 0,29 + 0,13 8,30 + 8,70 16,00 + 14,50 PAI-I activity [U/ml] 7 , 1 9 + 5 , 1 6 2,64 + 3,02 3,25 + 4,48 PAI-2 antigen [ng/ml] 1,09 + 1,52 PAP complexes lug/L] 181,0 + 68,0 178,0 ± 111,0 245,0 ± 263,0 * p<
0,001G.d~ ve~stm
~Lp.@. ; p < 0,05 G.d. m
cmxtt'ot"
Fibrinolytic passmeters in blood of patients with n-p.8, were similar to controls. Except ofu-PA, the parameters in G.d. were slightly higher than in controls. In G.ct i. comparison to controls and to n.p.& t-PA Ag was significantly higher, what could be effect o f thyroid hyper~ophia or liver dysfimction during hyperthyreosis.
171
172
TIlE FIBRINOLYTIC ACI'IVITY IN BI~OOI) (IF PATIENTS WITII LIVER CIRRllOSIS
VON WILLEBRAND FACTOR (vW 0 AND TISSUE PLASMINOGEN ACTIVATOR ANTIGEN (t-PA Ag) IN SOME THYROID DISEASES. 2Drewniak W., 'Znstawna E., t R o ~ D., 'Kulwns A., 'Pacznski P,. IDeparlments ofPathophysiolo~,, 2Diabetolo$y and ~ i o $ y , University School of Medical Sciences, Bydgoszcz, Poland
'Piatkowska M, 'Kotsehy M and =llaiota W 'Departments of Pathophysiology and 2Clinic of Infectious Diseases. Medical Akademy. Bydgoszcz. Poland. Severe hemorrhagic complications are often found in chronic liver disease. Accelerated fibrinolysis has long been recognised as a prominent finding. The aim of our work was the determination of tissue plasminogen activator/t-PA/and plasminogen activator inhibitor type 1 /PAl-l/in patients with different stages of liver cirrhosis and compared the data with healthy individuals and correlated the fibrynoblic data to established parameters of liver function. The examined group consisted of 65 patients x*,ithliver cirrhosis aged 36-76 /min.52.6/years in diiferent stage of liver damage in A.B and C Childs classification. The controll group consist of 36 healthy individuals. The citrate blood were collected between 8.00 and 10.00 A.M. xdth minimal venus occlusion. The antigen concentration of t-PA:Ag and PAl-hAg were determined xdth ELISA technique. The activi~"of t-PA:ac and PAl- 1:ac ~ere determined ,~ith chromogenic substrates. In blood of 65 patients x~ithliver cirrhosis as compared xdth control group increased concentration and activi~ of t-PA and decreased concentration and activity of PAI-I were observed.Changes of these parameters were going toegether with clinical and biochemical advance of cirrhosis. We could demonstrate a significant correlatin betxxeen albumin plasma concentration and t-PA:Ag and t-PA:ac values and possitive correlation between albumin and PAl-1 :Ag and PAl-1 :ac values.Our data suggest enhancement of fibrinolysis in severe liver cirrhosis and may be an important mechanism for bleeding in such patients.
5
The thyroid gland is the tissue rich in the plasminogen activators. In thyroid diseases,especially in Graves disease, the etructm~ o f g l m d is changed depending on hypervas©ularisation of tissue. The aim of study was to compare behaving of vWf and t-PA A8 ( markers of vascular endothelium distmbances ) in some thyroid diseases. The stedy was performed in p~tieets with nodular parenchymatons goitre ( n.p.g ; nffil8 ; aged 19-53 ), in Graves disease (G.d.; n=8; aged 22-45 ) and in toxic goieve ( t_g ; n=2 ; in age 45 and 55 ). The control ~voup consisted ot"22 healthy persons aged 24-50. [a ttxe biood cou~eatr~omt of vWf aad t-PA Ag were determined using ELISA.
Results : parameters vWf[%] t-PA Ag [ng/ml]
controls 103,7 + 20~9 5,62 + 3,72
n.p.g. 128,7 + 49~9 4,36 + 2,25
G.d. 192,9 + 64,6" 9,10 -t-4,20*
tg. 254,0 ; 180,0 7,2 ; 15,8
* p < 0,05 G.d. v~As control and rLp.g
In (kaves disease vWf and t-PA A8 concenha~ions were significantly higher finn in controls and in n p . g patients. The increase o f v W f a n d t-PA A 8 in Cn'aves disease could be the evidence of file intensive release of them by vasculm" endothelium of the hypertrophic thyroid glandule.
169
170
TISSUE PLASMINOGEN ACTIVAIOR AND PLASMINOGEN ACTIVATOR INHIBITOR IN AQUEOS HUMOR OF THE HUMAN EYE
t-PA, u-PA AND SOME OTHER FIBRINOLYTIC PARAMETERS IN N O D ~ PARENCHYMATOUS GOITRE AND GRAVES DISEASE 'Zastawna E., 2Drewniak W., 'Ro~ D., 'Zekanowska E ,
~Giedroj6 J,
1Bielawiec Stankiewicz A
M,
iDepartment of Hematology, University Medical School,
2Walkowiak
M,
iGalar
M,
20epartment of Ophthalmology Bialystok, Poland.
In the anterior segment of the eye, fibrin clots must be rapidly resorbed to prevent fibrosis. Tissue-type plasminogen activator (t-PA), a serine protease that catalyzes the conversion from plasminogen to plasmin plays an important role in the fibrinolytic system and has also in recent years attracted attention in the field of ophthalmology. ~he aqueous humor of patients undergoing cataract surgery was analyzed for the presence of components of the fibrinolytic cascade. The quantities of t-PA and plasminogen-activator inhibitor (PAl) were determined by using enzyme-linked immunosorbent assays. We determined t-PA and PAI in the aqueous humor of 64 patients between 59 and 82 years age. The t-PA levels ranged from 0.65 to 1.75 ng/ml and PAl activity from 3.24 to 5.1 AU/ml. Association between t-PA levels and PAI activity and acompanying diseases or metabolic disorders was noted. The highest concentration of t RA and the lowest activity of PAI in aqueous humor of patients with senile cataract has been observed. The knowledge about the presence of t-PA in aqueous humor is a equisite for the recognition of pathological events following intraocular fibrin formation and may be important basis for therapeutic use of t-PA.
'Gbralczyk B., 'Michalski A., 'Kotschy M.
Departments of'Pathophysiolo~, 2Endocrinolo~ and Diabetolosy, University School of Medical Sciences, Bydgo~zcz, Poland The aim of study was to compare the fibrinolytic potential in patients suffering fi'om nodular pafenchymatons goilre (rip.g) and Graves disease (G.d.),The study was performed in the blood plasma of 19 patients aged 19-53 (mean 34) with np.g. and in 8 patients aged 22-45 (mean 37) with G.d..Control group consisted of 22 healthy persons aged 24-50 (mean 36) .The following determinations were performed : t-PA and u-PA antigen and activity, PAI-1 activity, PAL2 antigen and PAP complexes.
Results: Parameters [twits]
Controls
rtp.g
G.d
n=14 n=19 n--8 9,10 ± 4,17 * 4,36 ±2,25 t-PA antigen [ng/ml] 5,62 + 3,72 0,81 + 0,46 t-PA activity [IU/mi] 0,52 + 0,21 0,56 + 0,33 0,53 ± 0,10 u-PA antigen [ng/ml] 0,59 ± 0,19 0,49 + 0,22 0,35 ± 0,08 0,37 + 0,13 u-PA activity [ng/ml] 0,29 + 0,13 8,30 + 8,70 16,00 + 14,50 PAI-I activity [U/ml] 7 , 1 9 + 5 , 1 6 2,64 + 3,02 3,25 + 4,48 PAI-2 antigen [ng/ml] 1,09 + 1,52 PAP complexes lug/L] 181,0 + 68,0 178,0 ± 111,0 245,0 ± 263,0 * p<
0,001G.d~ ve~stm
~Lp.@. ; p < 0,05 G.d. m
cmxtt'ot"
Fibrinolytic passmeters in blood of patients with n-p.8, were similar to controls. Except ofu-PA, the parameters in G.d. were slightly higher than in controls. In G.ct i. comparison to controls and to n.p.& t-PA Ag was significantly higher, what could be effect o f thyroid hyper~ophia or liver dysfimction during hyperthyreosis.
171
172
TIlE FIBRINOLYTIC ACI'IVITY IN BI~OOI) (IF PATIENTS WITII LIVER CIRRllOSIS
VON WILLEBRAND FACTOR (vW 0 AND TISSUE PLASMINOGEN ACTIVATOR ANTIGEN (t-PA Ag) IN SOME THYROID DISEASES. 2Drewniak W., 'Znstawna E., t R o ~ D., 'Kulwns A., 'Pacznski P,. IDeparlments ofPathophysiolo~,, 2Diabetolo$y and ~ i o $ y , University School of Medical Sciences, Bydgoszcz, Poland
'Piatkowska M, 'Kotsehy M and =llaiota W 'Departments of Pathophysiology and 2Clinic of Infectious Diseases. Medical Akademy. Bydgoszcz. Poland. Severe hemorrhagic complications are often found in chronic liver disease. Accelerated fibrinolysis has long been recognised as a prominent finding. The aim of our work was the determination of tissue plasminogen activator/t-PA/and plasminogen activator inhibitor type 1 /PAl-l/in patients with different stages of liver cirrhosis and compared the data with healthy individuals and correlated the fibrynoblic data to established parameters of liver function. The examined group consisted of 65 patients x*,ithliver cirrhosis aged 36-76 /min.52.6/years in diiferent stage of liver damage in A.B and C Childs classification. The controll group consist of 36 healthy individuals. The citrate blood were collected between 8.00 and 10.00 A.M. xdth minimal venus occlusion. The antigen concentration of t-PA:Ag and PAl-hAg were determined xdth ELISA technique. The activi~"of t-PA:ac and PAl- 1:ac ~ere determined ,~ith chromogenic substrates. In blood of 65 patients x~ithliver cirrhosis as compared xdth control group increased concentration and activi~ of t-PA and decreased concentration and activity of PAI-I were observed.Changes of these parameters were going toegether with clinical and biochemical advance of cirrhosis. We could demonstrate a significant correlatin betxxeen albumin plasma concentration and t-PA:Ag and t-PA:ac values and possitive correlation between albumin and PAl-1 :Ag and PAl-1 :ac values.Our data suggest enhancement of fibrinolysis in severe liver cirrhosis and may be an important mechanism for bleeding in such patients.
5
The thyroid gland is the tissue rich in the plasminogen activators. In thyroid diseases,especially in Graves disease, the etructm~ o f g l m d is changed depending on hypervas©ularisation of tissue. The aim of study was to compare behaving of vWf and t-PA A8 ( markers of vascular endothelium distmbances ) in some thyroid diseases. The stedy was performed in p~tieets with nodular parenchymatons goitre ( n.p.g ; nffil8 ; aged 19-53 ), in Graves disease (G.d.; n=8; aged 22-45 ) and in toxic goieve ( t_g ; n=2 ; in age 45 and 55 ). The control ~voup consisted ot"22 healthy persons aged 24-50. [a ttxe biood cou~eatr~omt of vWf aad t-PA Ag were determined using ELISA.
Results : parameters vWf[%] t-PA Ag [ng/ml]
controls 103,7 + 20~9 5,62 + 3,72
n.p.g. 128,7 + 49~9 4,36 + 2,25
G.d. 192,9 + 64,6" 9,10 -t-4,20*
tg. 254,0 ; 180,0 7,2 ; 15,8
* p < 0,05 G.d. v~As control and rLp.g
In (kaves disease vWf and t-PA A8 concenha~ions were significantly higher finn in controls and in n p . g patients. The increase o f v W f a n d t-PA A 8 in Cn'aves disease could be the evidence of file intensive release of them by vasculm" endothelium of the hypertrophic thyroid glandule.